Analysis of the mamma print breast cancer assay in a predominantly postmenopausal cohort

Ben S. Winner, Dennis C. Sgroi, Paula D. Ryan, Tako J. Bruinsma, Annuska M. Glas, Anitha Male, Sonika Dahiya, Karleen Habin, Rene Bernards, Daniel A. Haber, Laura J. Van't Veer, Sridhar Ramaswamy

Research output: Contribution to journalArticlepeer-review

117 Scopus citations

Abstract

Purpose: Most node-negative breast cancer patients are older and postmenopausal and are increasingly being offered adjuvant chemotherapy despite their low overall risk of distant relapse. A molecular diagnostic test with high negative predictive value (NPV) for distant metastasis in this subgroup would spare many older breast cancer patients adjuvant treatment. Experimental Design: We determined the NPVand positive predictive value of the Mamma Print assay in breast cancer patients who were consecutively diagnosed and treated at the Massachusetts General Hospital between 1985 and 1997. Primary tumors from 100 patients with node- negative, invasive breast cancer (median age, 62.5 years; median follow-up, 11.3 years) were subjected to MammaPrint analysis and classified as being at either low or high risk for distant metastasis. Results: The MammaPrint 70-gene signature displayed excellent NPV as in previous studies, correctly identifying 100% of women at low risk for distant metastases at 5 years. However, this assay had a lower positive predictive value (12% at 5 years) than previously observed. Conclusions: The MammaPrint assay was originally designed to identify younger breast cancer patients at low risk for distant metastasis, who might consequently be spared systemic treatment. We show here that the same signature has a very high NPV for distant recurrence after adjuvant treatment in older breast cancer patients.

Original languageEnglish
Pages (from-to)2988-2993
Number of pages6
JournalClinical Cancer Research
Volume14
Issue number10
DOIs
StatePublished - May 15 2008

Fingerprint

Dive into the research topics of 'Analysis of the mamma print breast cancer assay in a predominantly postmenopausal cohort'. Together they form a unique fingerprint.

Cite this